Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by AYSEGUL A SAHIN and LAVINIA P MIDDLETON.
AYSEGUL A SAHIN
Connection Strength
2.277
LAVINIA P MIDDLETON
  1. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features. Cancer. 2003 Sep 01; 98(5):1055-60.
    View in: PubMed
    Score: 0.228
  2. Lobular carcinoma in situ diagnosed by core needle biopsy: when should it be excised? Mod Pathol. 2003 Feb; 16(2):120-9.
    View in: PubMed
    Score: 0.219
  3. Sentinel lymph node histopathology in breast cancer. Am J Surg Pathol. 2002 Oct; 26(10):1368; author reply 1368.
    View in: PubMed
    Score: 0.214
  4. Multicentric mammary carcinoma: evidence of monoclonal proliferation. Cancer. 2002 Apr 01; 94(7):1910-6.
    View in: PubMed
    Score: 0.207
  5. Breast pathology second review identifies clinically significant discrepancies in over 10% of patients. J Surg Oncol. 2015 Feb; 111(2):192-7.
    View in: PubMed
    Score: 0.123
  6. Occult axillary lymph node metastases do not have prognostic significance in early stage breast cancer. Cancer. 2012 Mar 15; 118(6):1507-14.
    View in: PubMed
    Score: 0.099
  7. Glutathione-s-transferase-pi expression in early breast cancer: association with outcome and response to chemotherapy. Cancer Invest. 2010 Jun; 28(5):554-9.
    View in: PubMed
    Score: 0.091
  8. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer. Cancer. 2009 Apr 15; 115(8):1605-12.
    View in: PubMed
    Score: 0.084
  9. Neovascularization in mucinous ductal carcinoma in situ suggests an alternative pathway for invasion. Histopathology. 2008 Nov; 53(5):545-53.
    View in: PubMed
    Score: 0.082
  10. IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas. Breast J. 2008 May-Jun; 14(3):261-7.
    View in: PubMed
    Score: 0.078
  11. Expression of ERalpha and ERbeta in lobular carcinoma in situ. Histopathology. 2007 Jun; 50(7):875-80.
    View in: PubMed
    Score: 0.074
  12. HER-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger. Cancer. 2005 Mar 01; 103(5):900-5.
    View in: PubMed
    Score: 0.063
  13. Nuclear staining for pan-Trk by immunohistochemistry is highly specific for secretory carcinoma of breast: pan-Trk in various subtypes of breast carcinoma. J Clin Pathol. 2024 Oct 20; 77(11):751-755.
    View in: PubMed
    Score: 0.062
  14. Expression of c-kit proto-oncogene product in breast tissue. Breast J. 2004 Jul-Aug; 10(4):323-7.
    View in: PubMed
    Score: 0.060
  15. Accuracy of core needle biopsy diagnosis in assessing papillary breast lesions: histologic predictors of malignancy. Mod Pathol. 2004 Feb; 17(2):165-71.
    View in: PubMed
    Score: 0.059
  16. A Comparative Evaluation of TRPS1 and GATA3 in adenoid cystic, secretory, and acinic cell carcinomas of the breast and salivary gland. Hum Pathol. 2024 03; 145:42-47.
    View in: PubMed
    Score: 0.059
  17. Multicentric mammary carcinoma: evidence of monoclonal proliferation. Cancer. 2003 Feb 01; 97(3):715-7; author reply 717.
    View in: PubMed
    Score: 0.055
  18. Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma. Cancer. 2002 Jun 15; 94(12):3107-14.
    View in: PubMed
    Score: 0.052
  19. E-cadherin immunohistochemical analysis of histiocytoid carcinoma of the breast. Ann Diagn Pathol. 2002 06; 6(3):141-7.
    View in: PubMed
    Score: 0.052
  20. Metastatic nonhematopoietic neoplasms to the breast: a study of 238 cases. Hum Pathol. 2022 07; 125:59-67.
    View in: PubMed
    Score: 0.052
  21. TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma. Hum Pathol. 2022 07; 125:97-107.
    View in: PubMed
    Score: 0.052
  22. Recommendations for sentinel lymph node processing in breast cancer. Am J Surg Pathol. 2002 Mar; 26(3):377-82.
    View in: PubMed
    Score: 0.051
  23. Expression of TRPS1 in phyllodes tumor and sarcoma of the breast. Hum Pathol. 2022 03; 121:73-80.
    View in: PubMed
    Score: 0.051
  24. Prognostic significance of tumor grading and staging in mammary carcinomas with neuroendocrine differentiation. Hum Pathol. 2011 Aug; 42(8):1169-77.
    View in: PubMed
    Score: 0.024
  25. Is it too soon to start reporting HER2 genetic heterogeneity? Arch Pathol Lab Med. 2010 Feb; 134(2):162-3; author reply 163.
    View in: PubMed
    Score: 0.022
  26. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg. 2006 Feb; 243(2):257-64.
    View in: PubMed
    Score: 0.017
  27. Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer. 2005 Apr 15; 103(8):1581-6.
    View in: PubMed
    Score: 0.016
  28. Factors predictive of having four or more positive axillary lymph nodes in patients with positive sentinel lymph nodes: implications for selection of radiation fields. Int J Radiat Oncol Biol Phys. 2004 Jul 15; 59(4):1074-9.
    View in: PubMed
    Score: 0.015
  29. Histologic localization of sentinel lymph node metastases in breast cancer. Am J Surg Pathol. 2003 Mar; 27(3):385-9.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.